Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8787819 | Journal of Thoracic Oncology | 2018 | 7 Pages |
Abstract
Trastuzumab emtansine (T-DM1), an anti-erb-b2 receptor tyrosine kinase 2 (HER2) antibody-drug conjugate, has been shown to significantly improve survival in HER2-positive breast cancer. We report a phase II trial of T-DM1 monotherapy in relapsed NSCLC with documented HER2 positivity (an immunohistochemistry [IHC] score of 3+, both an IHC score of 2+ and fluorescence in situ hybridization positivity, or exon 20 mutation). This study was terminated early because of limited efficacy. The demographic characteristics in the 15 assessable patients were as follows: median age, 67 years; male sex, 47%; performance status of 0 to 1, 80%; HER2 status IHC 3+, 33%; HER status IHC 2+/fluorescence in situ hybridization-positive, 20%; and exon 20 mutation, 47%. The median number of delivered cycles was 3 (range 1-11). One patient achieved a partial response with an objective response rate of 6.7% (90% confidence interval: 0.2-32.0). With a median follow-up time of 9.2 months, the median progression-free survival time and median survival time were 2.0 and 10.9 months, respectively. Grade 3 or 4 adverse events included thrombocytopenia (40%) and hepatotoxicity (20%) without any treatment-related deaths. T-DM1 had a limited efficacy for HER2-positive NSCLC in our cohort. Applying the concept of precision medicine to tumors appears challenging; thus, additional molecular approaches are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Katsuyuki MD, PhD, MPH, Keisuke MD, PhD, Toshiyuki MD, PhD, Kadoaki MD, PhD, Kiichiro MD, Eiki MD, PhD, Toshio MD, PhD, Takashi MD, PhD, Kenichi MD, PhD, Daijiro MD, PhD, Naoyuki MD, PhD, Taizo MD, PhD, Shiro MD, PhD, Shinichi MD, PhD, Katsuyuki MD, PhD,